In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $41.50 in the prior trading day, Celldex Therapeutics Inc. (NASDAQ: CLDX) closed at $44.54, up 7.33%. In other words, the price has increased by $7.33 from its previous closing price. On the day, 0.98 million shares were traded. CLDX stock price reached its highest trading level at $45.08 during the session, while it also had its lowest trading level at $41.0864.
Ratios:
Our goal is to gain a better understanding of CLDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.36 and its Current Ratio is at 29.36. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on June 18, 2024, initiated with a Buy rating and assigned the stock a target price of $58.
On June 11, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $51.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 14 ’24 when Martin Samuel Bates sold 17,172 shares for $35.42 per share. The transaction valued at 608,315 led to the insider holds 28,125 shares of the business.
Crowley Elizabeth sold 30,000 shares of CLDX for $1,045,962 on Jun 14 ’24. The SR. VP & CPDO now owns 9,074 shares after completing the transaction at $34.87 per share. On Jun 07 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 15,000 shares for $35.06 each. As a result, the insider received 525,873 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2952449792 and an Enterprise Value of 1951003264. For the stock, the TTM Price-to-Sale (P/S) ratio is 355.73 while its Price-to-Book (P/B) ratio in mrq is 3.63. Its current Enterprise Value per Revenue stands at 234.976 whereas that against EBITDA is -12.179.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is 20.21%, while the 200-Day Moving Average is calculated to be 17.56%.
Shares Statistics:
The stock has traded on average 712.46K shares per day over the past 3-months and 607180 shares per day over the last 10 days, according to various share statistics. A total of 66.29M shares are outstanding, with a floating share count of 64.20M. Insiders hold about 3.15% of the company’s shares, while institutions hold 103.28% stake in the company. Shares short for CLDX as of 1723680000 were 8661767 with a Short Ratio of 12.16, compared to 1721001600 on 7390703. Therefore, it implies a Short% of Shares Outstanding of 8661767 and a Short% of Float of 15.120000000000001.
